Urovant Sciences (UROV) Reports Q2 Loss of $1.23

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. BA
4. STX
5. NXPI
6. SPY
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Urovant Sciences (UROV) Reports Q2 Loss of $1.23

Urovant Sciences (UROV) Reports Complete Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder

November 8, 2018 8:15 AM EST

Urovant Sciences (NASDAQ: UROV) today announced it completed enrollment in its international Phase 3 clinical trial, EMPOWUR, evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder. Vibegron is an investigational oral beta-3 adrenergic agonist.

I am proud of the progress made since initiating our robust EMPOWUR clinical trial in March of 2018, said Dr. Cornelia Haag-Molkenteller, Chief Medical Officer of Urovant. Exceeding our enrollment ahead of schedule underscores the interest in this trial and reinforces the need for this significantly underserved patient population.

EMPOWUR is a randomized, double-blind... More